Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozurdex versus ranibizumab with laser therapy for severe Coats' disease
ChiCTR2400094335Phase 4Not yet recruiting
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Dec 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial in Coats disease comparing Ozurdex with laser therapy group with Ranibizumab with laser therapy group (2 arms). Primary endpoints: Best corrected visual acuity and Retinal abnormal vascular regression rate. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
ozurdexranibizumab
03
Conditions
Coats disease
Beyond the preview
Go deeper on ChiCTR2400094335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094335.